AMMF Hosts International Cholangiocarcinoma Conference 2018 in UK on Latest Advances for World's Second Most Common Primary Liver Cancer Which Continues to See Worrying Rise in New Cases Amongst Younger People
STANSTED, England, April 25, 2018 (Newswire.com) - AMMF, the only charity in the UK dedicated to cholangiocarcinoma (bile duct cancer) will again bring together scientists, researchers, medics and patients from across the globe at its BASL endorsed conference on 10 May 2018 from 08:30 - 20:00 at the Radisson Blu Hotel, Stansted Airport, Essex.
The conference programme will include updates from leading UK and international experts on issues ranging from surgery for cholangiocarcinoma to the latest clinical trials and targeted therapies for cancer, including the use of radiation therapy (RT). This year will also see the official presentation of the new AMMF Cholangiocarcinoma Scholarship, a 3-year PhD award funded by the charity to specifically to investigate the role of mutations in cholangiocarcinoma. Mollie King, the first recipient of the Scholarship, will be based at The Boulter Lab, located in the MRC Human Genetics Unit at the University of Edinburgh and one of the UK’s foremost laboratories researching cholangiocarcinoma.
As well as welcoming world-class specialists we are delighted to have some of our loyal supporters and fundraisers join us to share their personal experience with cholangiocarcinoma. The chance for people to meet medical experts and hear survivors' stories plays a vital part in helping to foster dialogue to improve awareness of this neglected disease, the incidence of which appears to be rising across all age groups, including younger people.
Helen Morement, Chief Executive, AMMF
As well as Two Patient Speakers, the 13 Specialist Presenters at this year’s Conference include: -
Dr Shahid Khan, Imperial College London
Dr Hayley Whitaker, University College London
Dr Simon Rushbrook Norfolk & Norwich University Hospital
Professor David Bates, University of Nottingham
Mr Marc Quinn, University of Liverpool
Dr Luke Boulter, University of Edinburgh
Dr Ben Dwyer, University of Edinburgh
Professor Richard Syms, Imperial College London
Professor Robert Goldin, Imperial College London
Mr Hassan Malik, Aintree University Hospital
Dr Chris Wadsworth, Imperial College London
Professor Maria Hawkins, University of Oxford
Professor Juan Valle, The Christie, Manchester
As Helen Morement, founder and CEO of the AMMF explains, “Although cholangiocarcinoma (bile duct cancer) is the second most common primary liver cancer in the world, with an increasing incidence globally, and despite its appalling survival rates due to late diagnosis and few treatment options, it remains poorly understood and under-researched. AMMF’s annual cholangiocarcinoma conference is a key platform, unique in the UK, for international experts to share news and information about clinical studies and latest research. The findings bring the prospect of early diagnosis and more effective treatments one step closer.”
“The fact that the conference is now BASL endorsed will help to signpost AMMF as a UK organisation committed to advancing knowledge and understanding of the biology and pathology of the liver in our specialised field, as we work towards better diagnostic techniques, treatments, and ultimately a cure, for this devastating cancer.”
There is no fee for professional delegates, patients, and carers to attend AMMF’s Cholangiocarcinoma Conference - it is open to all who have an interest in this disease. To see the full programme for the day, click here.
Ends
Contact
Esther Porta at AMMF on: +44 (0) 20 7351 7374 or +44 (0)7870 439158 Email: esther@ammf.org.uk
About AMMF
AMMF was founded and registered as a charity with the Charity Commission in 2002 (registered charity no 1091915). AMMF is the UK’s only cholangiocarcinoma charity, dedicated to tackling this devastating cancer on all fronts: providing information and support, campaigning to raise awareness, and encouraging and supporting research. In recent years an enormous and extremely worrying worldwide increase in cholangiocarcinoma’s incidence has been noted. Latest figures show there were 2,161 deaths caused by cholangiocarcinoma in 2013 in England alone (NCIN/Cancer52 report). The incidence appears to be increasing across all age groups, including younger people, and the cause of this ongoing increase is unknown. Much more research is desperately needed.
AMMF is dedicated to bringing about improvement for the cholangiocarcinoma patient, working closely throughout the UK with patients, families, carers, clinicians, healthcare professionals, researchers, politicians and policymakers, and collaborating internationally. For more information visit: www.ammf.org.uk (registered charity no.1091915).
Source: AMMF